Pfizer Inc. (PFE)
| Market Cap | 157.65B +15.3% |
| Revenue (ttm) | 63.70B -0.2% |
| Net Income | 4.33B -59.7% |
| EPS | 0.76 -59.9% |
| Shares Out | 5.70B |
| PE Ratio | 36.36 |
| Forward PE | 9.98 |
| Dividend | $1.72 (6.22%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 75,593,388 |
| Open | 27.64 |
| Previous Close | 27.64 |
| Day's Range | 27.34 - 27.66 |
| 52-Week Range | 23.58 - 29.21 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 28.88 (+4.41%) |
| Earnings Date | Nov 3, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for PFE stock is "Buy." The 12-month stock price target is $28.88, which is an increase of 4.41% from the latest price.
News
Pfizer to share portion of increased revenue to U.S. HHS, Bloomberg says
The U.S. Department of Health and Human Services, HHS, will receive a portion of the increased revenue if Pfizer (PFE) raises its drug prices abroad, Rachel Cohrs Zhang of Bloomberg…
Health Canada authorizes Pfizer, BioNTech’s Omicron XFG-adapted Covid-19 vaccine
Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the XFG variant-adapted COMIRNATY for active immunization of individuals aged 6 months and older against COVID-19. T...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Exe...
Pfizer Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Key 2025 headwinds have been resolved, shifting focus to pipeline and business development. Major investments in innovation, especially in China, and AI deployment are expected to drive future growth. Upcoming catalysts include a robust obesity portfolio and pivotal oncology readouts.
Pfizer aims at air-traffic controllers for Covid-19 vaccine money, WSJ says
In an attempt to get paid for millions of unwanted Covid-19 vaccines, Pfizer (PFE) is taking aim at air-traffic controllers, Benjamin Katz of The Wall Street Journal reports. The company…
Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.
Pfizer price target raised to $30 from $28 at HSBC
HSBC raised the firm’s price target on Pfizer (PFE) to $30 from $28 and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare group to…
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
Vaxcyte (PCVX) announced the appointments of Luis Jodar as chief medical officer and David McAvoy as chief legal officer. Jodar spent 17 years at Pfizer (PFE), most recently as senior…
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonali...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine
Pfizer (PFE) and BioNTech (BNTX) announced that the FDA has approved the supplemental Biologics License Application for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant, COM...
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved t...
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Pfizer, Valneva announce EMA validation for PF-07307405 MAA
Pfizer (PFE) and Valneva (VALN) announced that the European Medicines Agency, or EMA, has validated the marketing authorization application, or MAA, for PF-07307405, the companies’ 6-valent outer surf...
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase
Three Pfizer insiders executed transactions directly on the heels of the drugmaker's second-quarter earnings report.
Closed Pfizer biopharma facility in Everett gets a new lease on life
A biomanufacturing facility in Everett that Pfizer decided to shut down before it opened is getting a new lease on life, with a new owner and a 21-year lease to an unnamed global biopharmaceutical com...
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Pharmaceutical company Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. Approved by the FDA in May 2006 as a smoking-cessation aid, the drug wa...
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketin...
Pfizer Earnings Call Transcript: Q2 2026
Q2 2026 revenue and adjusted EPS exceeded expectations, driven by strong growth in launched and acquired products, especially in oncology and migraine. Full-year revenue guidance was raised, with continued cost savings initiatives and a reaffirmed dividend commitment.
Pfizer Earnings release: Q2 2026
Pfizer released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Pfizer Slides: Q2 2026
Pfizer has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Pfizer Quarterly report: Q2 2026
Pfizer has published its Q2 2026 quarterly earnings report on August 4, 2026.